Forte Biosciences (FBRX) Net Cash Flow Growth (3y) (2019 - 2026)
Forte Biosciences (FBRX) Net Cash Flow Growth (3y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 38.47% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Forte Biosciences | 174.08 Mn | 115.88 Mn | - | -53.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -53.30% |
| Dec 31, 2025 | -77.46% |
| Sep 30, 2025 | -62.80% |
| Jun 30, 2025 | 249.10% |
| Mar 31, 2025 | 139.59% |
| Dec 31, 2024 | 53.60% |
| Sep 30, 2024 | -16.61% |
| Jun 30, 2024 | -14.44% |
| Mar 31, 2024 | -18.62% |
| Dec 31, 2023 | -30.74% |
| Sep 30, 2023 | 75.43% |
| Jun 30, 2023 | -35.80% |
| Mar 31, 2023 | -36.17% |
| Dec 31, 2022 | -58.38% |
| Sep 30, 2022 | 42.12% |
| Jun 30, 2022 | -27.63% |
| Mar 31, 2022 | 41.07% |
| Dec 31, 2021 | -30.23% |
| Sep 30, 2021 | -65.53% |
| Jun 30, 2021 | -37.18% |